These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38964788)

  • 1. Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
    Willoughby JE; Dou L; Bhattacharya S; Jackson H; Seestaller-Wehr L; Kilian D; Bover L; Voo KS; Cox KL; Murray T; John M; Shi H; Bojczuk P; Jing J; Niederer H; Shepherd AJ; Hook L; Hopley S; Inzhelevskaya T; Penfold CA; Mockridge CI; English V; Brett SJ; Srinivasan R; Hopson C; Smothers J; Hoos A; Paul E; Martin SL; Morley PJ; Yanamandra N; Cragg MS
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
    Griffiths J; Hussain K; Smith HL; Sanders T; Cox KL; Semmrich M; Mårtensson L; Kim J; Inzhelevskaya T; Penfold CA; Tutt AL; Mockridge CI; Chan HC; English V; French RF; Teige I; Al-Shamkhani A; Glennie MJ; Frendeus BL; Willoughby JE; Cragg MS
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
    Pratico ED; Sullenger BA; Nair SK
    Nucleic Acid Ther; 2013 Feb; 23(1):35-43. PubMed ID: 23113766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model.
    Liu JJ; Su QD; Yi Y; Shen LP; Bi SL
    Biomed Environ Sci; 2024 Feb; 37(2):187-195. PubMed ID: 38582981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
    Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
    Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
    Imianowski CJ; Kuo P; Whiteside SK; von Linde T; Wesolowski AJ; Conti AG; Evans AC; Baird T; Morris BI; Fletcher NE; Yang J; Poon E; Lakins MA; Yamamoto M; Brewis N; Morrow M; Roychoudhuri R
    Cancer Res Commun; 2024 Aug; 4(8):2045-2057. PubMed ID: 38995700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
    Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
    Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
    Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
    J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
    Piconese S; Valzasina B; Colombo MP
    J Exp Med; 2008 Apr; 205(4):825-39. PubMed ID: 18362171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
    Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
    Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
    Manso T; Kushwaha A; Abdollahi N; Duroux P; Giudicelli V; Kossida S
    Front Immunol; 2023; 14():1129323. PubMed ID: 37215135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.